Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

n cancer cells, a protein that acts as a central regulator of tumor cell division, blood vessel growth and cell metabolism. Everolimus is being studied in multiple tumor types, including breast cancer, neuroendocrine tumors, gastric cancer, hepatocellular carcinoma (HCC) and non-Hodgkin lymphoma (NHL), as well as tuberous sclerosis complex (TSC).

As an investigational compound, the safety and efficacy profile of everolimus has not yet been established in these cancer and tumor types. Access to everolimus for these cancer and tumor types is available through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. For more information about everolimus clinical trials, healthcare professionals can visit www.theWIDEprogram.com. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will ever become commercially available for these cancer and tumor types anywhere in the world.

Afinitor (everolimus) tablets important safety information

Afinitor is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives or to any of the excipients. Potentially serious adverse reactions to Afinitor include non-infectious pneumonitis and infections, for which patients should be monitored carefully and treated as needed. In addition, non-infectious pneumonitis may require temporary dose reduction and/or interruption or discontinuation. Patients with systemic invasive fungal infections should not receive Afinitor. Oral ulceration is a common side effect of Afinitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to the start of therapy with Afinitor and periodically thereafter. Strong or moderate CYP3A4 or P-glycoprotein inhibitors should be avoided. An increase in the dose of Afinitor is
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 20, 2015 ... the addition of the "Cardiometabolic Drug News ... Afrezza,s discounted pricing is in line with our ... to the product,s commercial appeal. However, contraindications, side ... from gaining a sizeable share of the fast-acting ...
(Date:7/27/2015)... N.H. , July 27, 2015  Linear ... incredibly intricate machines, requiring not only adequate space ... vaults for their operation. Inherent to the size ... a linear accelerator or the addition of a ... hospital. Suspending operations risks interruption of patient treatment: ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ) has ... Receptors Market: Global Industry Analysis, Size, Share, Growth, ... to their offering. The global ... assay type, therapeutic area, and geography. Based on ... into six major segments: cAMP assays, calcium level ...
Breaking Medicine Technology:Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Accelerating the Design Process for Cancer Treatment Centers 2Accelerating the Design Process for Cancer Treatment Centers 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Pharma NV/SA, a rapidly growing pharmaceutical company specialising in ... Veeva CRM to support its salesforce in Belgium. Pharco ... application that was both pharma-specific and easily adaptable. The ... for the global pharma and biotech industry. ...
... New Zealand health technology company Medtech Global, ... collaborated to develop an electronic health information solution ... medical records of visiting international MedicAlert members in ... first" the long term vision for the solution ...
Cached Medicine Technology:Pharco Pharma NV/SA Leverages Advantages of Cloud Computing With the Implementation of Veeva CRM 2Pharco Pharma NV/SA Leverages Advantages of Cloud Computing With the Implementation of Veeva CRM 3Medtech and MedicAlert Create Global Connection for Rugby World Cup 2011 2Medtech and MedicAlert Create Global Connection for Rugby World Cup 2011 3
(Date:7/27/2015)... ... July 27, 2015 , ... ... One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... the first things FDA investigators will look at during an inspection. Yet, ...
(Date:7/27/2015)... ... 27, 2015 , ... On July 14, 2015, Harper’s Bazaar Magazine in an ... skin issues such as stretch marks , fine lines , and ... treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital ... The center invites all those prospective joint-replacement patients, along with their friends and family ... month, with Monday classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing program of ... its options. Already an industry leader because of its use of iPad technology ... latest successful trends in helping people to overcome addiction and live healthy, productive ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... says more programs needed for transition to adult health care ... arthritis need more help and information when they approach adulthood ... new study shows. , The study, led by Peter Scal ... of adolescents with arthritis received counseling on issues such as ...
... Drain NEW YORK, Jan. 13 New York Blood ... City, Long Island, Hudson Valley and New Jersey) have ... demand for blood (needed for emergency care and surgery) ... donation have been below forecast. Blood supplies have ...
... Goldring smiles as she shows a visitor photos she,s taken ... The demonstration comes more than 20 years after Goldring, a ... colleagues began work on a "seeing machine" that can allow ... the Internet, view the face of a friend and much ...
... New Version Increases Physician AccessSUNNYVALE, Calif., Jan. 13 ... version of the Pathwork(R) Tissue of Origin Test ... (FFPE) tissue specimens. This molecular diagnostic test, which ... origins, is now available as a service through ...
... 13, 2009) The American Journal of Nursing ... healthcare publications of 2008 with an announcement today of ... 15 separate categories appear in the journal,s January issue. ... of controversial consumer health topics and nursing industry issues ...
... Fla., Jan. 13 Zassi Medical,Evolutions(R), a privately ... and development, today announced the launch of e-Zassi(TM) ... the medical,device industry by streamlining diligence, collaboration and ... an exclusive array of,intelligent Web-based applications. , ...
Cached Medicine News:Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 2Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 5Health News:MIT develops camera for the blind 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 3Health News:American Journal of Nursing announces 2008 Book of the Year Awards 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 3
... The SYNCHRON CX5-S workstation ... electrolyte testing, targeted to the ... than 200 samples per day. ... the CX5-S is easy to ...
... the high-volume lab, the SYNCHRON LX4201 simplifies ... up to 2,880 tests per hour. By ... SYNCHRON LX4201 with broad menu, speed and ... come to expect from Beckman Coulter-innovative, reliable ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... the power of the LX2000 Series ... resources without compromising testing quality.Plus, when ... LX20 PRO, you get advanced features ... other chemistry analyzer, including closed tube ...
Medicine Products: